Details About Generic Salt ::  Etodolac

Main Medicine Class:: Analgesic,NSAID   

(EE-toe-DOE-lak)

Lodine, Lodine XL

Class: Analgesic/NSAID

Drugs Class ::

 Action Decreases inflammation, pain and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.

Indications for Drugs ::

 Indications Management of pain (Lodine only); management of signs and symptoms of osteoarthritis and rheumatoid arthritis. Unlabeled use(s): Control of symptoms of rheumatoid arthritis; treatment of temporal arteritis.

Drug Dose ::

 Route/Dosage

Analgesia

ADULTS: PO 200 to 400 mg q 6 to 8 hr prn. Do not exceed 1200 mg/day. Patients £ 60 kg should not exceed 20 mg/kg.

Osteoarthritis/Rheumatoid Arthritis

ADULTS: PO 300 mg bid, tid, or 400 mg or 500 mg bid. The dose may be increased to 1200 mg/day when a higher level of therapeutic activity is required.

Contraindication ::

 Contraindications Patients in whom aspirin, iodides or any NSAID has caused allergic-type reactions.

Drug Precautions ::

 Precautions

Pregnancy: Category C: Lactation: Undetermined. Children: Safety and efficacy not established. Elderly or debilitated patients: Increased risk of adverse reactions. GI effects: Serious GI toxicity (eg, bleeding, ulceration, perforation) can occur at any time, with or without warning symptoms. Hypersensitivity: May occur; use caution in aspirin sensitive individuals because of possible cross-sensitivity. Renal effects: Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia and renal papillary necrosis may occur. Renal impairment: Assess renal function before and during therapy.

Drug Side Effects ::

 Adverse Reactions

CV: Fluid retention; edema; hypertension; flushing; CHF; syncope; palpitations. CNS: Dizziness; headaches; drowsiness; insomnia; asthenia; malaise; depression; nervousness. DERM: Rash; pruritus; Stevens-Johnson syndrome; hyperpigmentation; urticaria; purpura. EENT: Blurred vision; photophobia; visual changes; tinnitus. GI: Dyspepsia; nausea; vomiting; diarrhea; indigestion; heartburn; abdominal pain; constipation; flatulence; gastritis; melena; dry mouth; anorexia; stomatitis; peptic ulcers. GU: Urinary frequency; dysuria. HEMA: Anemia; leukopenia; pancytopenia; thrombocytopenia; increased bleeding time; agranulocytosis; hemolytic anemia; neutropenia. HEPA: Jaundice; cholestatic jaundice; hepatitis. META: Weight gain; hypouricemia. RESP: Asthma. OTHER: Chills; fever.

Drug Mode of Action ::  

 Action Decreases inflammation, pain and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.

Drug Interactions ::

 Interactions

Anticoagulants: May increase prothrombin time. Watch for signs and symptoms of bleeding. Beta-blockers: May decrease antihypertensive effect of beta-blockers. Lithium: May increase lithium levels and effects. Loop diuretics: May decrease diuretic effect. Methotrexate: May increase methotrexate levels. Salicylates: Plasma concentrations of NSAIDs may be decreased when taken with salicylates. There is no therapeutic advantage to this combination, but adverse GI effects may be increased.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies, especially to aspirin, iodides or other NSAIDs. Note history of GI bleeding.
• Assess location, duration and intensity of pain before and 60 min after administration.
• Monitor hematocrit and hemoglobin levels in patients on long-term therapy.
• Monitor for signs of agranulocytosis (sore throat, fever).
• Monitor renal function.
• Monitor for edema and weight gain in patients with CHF and renal impairment.
• Monitor PT/APTT levels of patients taking anticoagulants.
• Monitor elderly patients carefully for possible adverse reactions.
• Review liver function test results, and report signs of hepatic dysfunction to the physician.
• Discontinue drug if hypersensitivity develops.
• Inform physician of decreased renal function, hyponatremia and hyperkalemia laboratory values.

Extended-release

• After satisfactory response is achieved, usually after 1 to 2 wks, assess patient to determine if dose needs to be adjusted.

Drug Storage/Management ::

 Administration/Storage

• Do not give more than 20 mg/kg to patients weighing £ 60 kg.
• Food delays peak action of medication by 1–4 hr.
• Give with food, milk or antacids if stomach upset occurs.
• Store at room temperature in tightly closed container. Protect from moisture.

Drug Notes ::

 Patient/Family Education

• Advise patient to take medication with full glass of water and to remain upright for 15–30 min after administration.
• Encourage patient on long-term therapy to have regular eye examinations.
• Advise patient to inform physician or dentist of medication regimen before treatment or surgery.
• Instruct patient to report these symptoms to physician: rash, stomach problems, tinnitus, dizziness or visual disturbances, black tarry stools, increased bruises or bleeding.
• Caution patient not to use aspirin or other otc medications or drink alcoholic beverages while taking this medication.
• Advise patient that drug may cause drowsiness and to use caution while driving or performing tasks requiring mental alertness.
• Caution patient to avoid exposure to sunlight and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.